GlassScriptPhysician profile
Scott Yi Tong
NPI 1780181966
$4,099.83
in general payments reported to CMS, 2019-2025
26 companies · $1,819 in 2025
The $1,819 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $63.97 · 2021: $118 · 2022: $387 · 2023: $824 · 2024: $888 · 2025: $1,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $634.14 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $567.13 | 2020-2025 | |
| Abbvie INC. | $373.77 | 2022-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.72 | 2021-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $186.05 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $182.28 | 2023-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $176.48 | 2022-2025 | Shingrix, Bexsero, Arexvy |
| Janssen Pharmaceuticals, INC | $168.31 | 2023-2025 | Spravato |
| Merck Sharp & Dohme LLC | $161.52 | 2022-2024 | Belsomra, Capvaxive, Gardasil 9 |
| Supernus Pharmaceuticals, INC. | $141.38 | 2025 | Qelbree |
| Exact Sciences Corporation | $76.81 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $67.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $62.69 | 2024-2025 | Breztri, Airsupra |
| Axsome Therapeutics, INC. | $60.23 | 2025 | Auvelity |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $52.81 | 2025 | Azstarys |
| Sumitomo Pharma America, INC. | $51.16 | 2025 | Gemtesa |
| Organon LLC | $44.29 | 2024-2025 | Nexplanon |
| Shield Therapeutics INC | $43.98 | 2025 | |
| Astellas Pharma US INC | $31.26 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $25.44 | 2025 | Inspire |
| Dynavax Technologies Corporation | $20.25 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $17.58 | 2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $16.00 | 2022 | |
| Genentech USA, INC. | $13.57 | 2021 | |
| Dexcom, INC. | $12.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Tong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.